60 Degrees Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from 60 Degrees Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 98% of Healthcare companies in United States.
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $29 per $100 of sales comes from others' credit, against $174 from others' credit three years earlier. Less money tied up than 96% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 4,912% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 94% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-33.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 66% of Healthcare companies in United States.
Cash Locked Ratio
−$29Money owed to suppliers is larger than money owed by customers plus stock: $29 per $100 of sales comes from others' credit, against $174 from others' credit three years earlier.
Less money tied up than 96% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
−$151Sales grew 350% in 3 years, but profit fell: $151 less profit per $100 of extra sales.
Lower than 89% of Healthcare companies in United States.
Asset Productivity Ratio
+350% / +314%In 3 years sales changed by +350% while total assets changed by +314%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-780.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 98% of Healthcare companies in United States.
Cash Cushion Ratio
+44%Cash, after subtracting all debt, equals 44% of its market value (net cash).
Higher than 76% of Healthcare companies in United States.
Tangible Assets Ratio
96%Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 76% of Healthcare companies in United States.
Tangible Net Worth Ratio
94%Of every $100 of net worth, $94 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 78% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
60 Degrees Pharmaceuticals, Inc. made a loss over the last year. 60 Degrees Pharmaceuticals, Inc. owes $0.41 for every $1 it owns. 60 Degrees Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
Loss60 Degrees Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.18The share price is 1.18 times 60 Degrees Pharmaceuticals, Inc.'s book value per share, lower than 75% of Healthcare companies in United States.
Market cap
$3 MThe total market value of all of 60 Degrees Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 96% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$3 MWhat 60 Degrees Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.74Net worth divided by the number of shares. The share price of $0.88 is 1.2 times this, which is the P/B above.
Return on equity (ROE)
-332.9%60 Degrees Pharmaceuticals, Inc. lost 332.9% of its shareholders' money over the last year, lower than 89% of Healthcare companies in United States.
Owes vs Owns
0.41×60 Degrees Pharmaceuticals, Inc. owes $0.41 for every $1 it owns (low), lower than 51% of Healthcare companies in United States.
Dividend yield
None60 Degrees Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+65%Revenue rose 65% in the year to Dec 2025, and grew 65% a year on average over 3 years.
Profit growth
Loss60 Degrees Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-732.5%60 Degrees Pharmaceuticals, Inc. lost $733 for every $100 of revenue.
Interest cover
Not covered60 Degrees Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cash60 Degrees Pharmaceuticals, Inc. held $1 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For 60 Degrees Pharmaceuticals, Inc.: $3 M ÷ $3 M (30 Jun 2026) = 1.2.
What is 60 Degrees Pharmaceuticals, Inc.'s return on equity?
60 Degrees Pharmaceuticals, Inc. lost 332.9% of its shareholders' money over the last year, lower than 89% of Healthcare companies in United States.
How much does 60 Degrees Pharmaceuticals, Inc. owe compared with what it owns?
60 Degrees Pharmaceuticals, Inc. owes $0.41 for every $1 it owns (low), lower than 51% of Healthcare companies in United States.
Does 60 Degrees Pharmaceuticals, Inc. pay a dividend?
No. 60 Degrees Pharmaceuticals, Inc. does not currently pay a dividend.
Is 60 Degrees Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 65% in the year to Dec 2025, and grew 65% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.